news

NICE issues draft guidance, finding negative opinion for volanesorsen

3
SHARES

Waylivra (volanesorsen) has not been recommended for treatment of familial chylomicronaemia syndrome, according to draft guidance from NICE.

The UK National Institute for Health and Care Excellence (NICE) has announced draft guidance that it will not be recommending Waylivra (volanesorsen) for the treatment of familial chylomicronaemia syndrome (FCS).

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The company is now able to provide further clarification for public consultation”

Volanesorsen, produced by Akcea Therapeutics, was found to be beneficial in the short-term, but showed little benefit for the long-term.

NICE reports that there was also uncertainty as the main clinical trials used a different dose to the dosage described in the marketing authorisation for the drug.

Another doubt from the committee came from aspects of the company’s economic model, which were found to be highly uncertain. The cost-effectiveness estimates were much higher than what NICE considers acceptable for highly specialised technologies, leading to the decision that volanesorsen could not be recommended as an appropriate use of NHS resource.

The company is now able to provide further clarification for public consultation, which could determine the final decision on the drug. NICE has also recommended that Akcea Therapeutics carries out a further scenario analysis to explore the impact of the condition on health-related quality of life carers.

Volanesorsen is licensed for adults with FCS at high risk for pancreatitis who have not responded to diet and triglyceride-lowering therapy. The drug is administered as a once-weekly (decreasing to once-fortnightly after three months) 285mg injection. The list price of volanesorsen is £11,394 per single-use 285mg syringe.

Share via
Share via